Metabolic remodeling by the PD-L1 inhibitor BMS-202 significantly inhibits cell malignancy in human glioblastoma
Abstract Recently, crystallographic studies have demonstrated that BMS-202, a small-molecule compound characterized by a methoxy-1-pyridine chemical structure, exhibits a high affinity to PD-L1 dimerization. However, its roles and mechanisms in glioblastoma (GBM) remain unclear. The objective of thi...
Main Authors: | Xueou Yang, Wenjun Wang, Tianhai Ji |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2024-03-01
|
Series: | Cell Death and Disease |
Online Access: | https://doi.org/10.1038/s41419-024-06553-5 |
Similar Items
-
BMS‐202, a PD‐1/PD‐L1 inhibitor, decelerates the pro‑fibrotic effects of fibroblasts derived from scar tissues via ERK and TGFβ1/Smad signaling pathways
by: Yuanyuan Cai, et al.
Published: (2022-10-01) -
An improved cell line-derived xenograft humanized mouse model for evaluation of PD-1/PD-L1 blocker BMS202-induced immune responses in colorectal cancer
by: Shang Pengzhao, et al.
Published: (2022-10-01) -
Targeting HER2-positive breast cancer cells by a combination of dasatinib and BMS-202: Insight into the molecular pathways
by: Hadeel Kheraldine, et al.
Published: (2024-03-01) -
The conformal BMS group
by: Sasha J. Haco, et al.
Published: (2017-11-01) -
BMS-265246, a Cyclin-Dependent Kinase Inhibitor, Inhibits the Infection of Herpes Simplex Virus Type 1
by: Lefang Jiang, et al.
Published: (2023-07-01)